计算预测帕罗韦德与处方药之间的相互作用。
Computational prediction of interactions between Paxlovid and prescription drugs.
机构信息
Metabolic and Biomolecular Engineering National Research Laboratory, Department of Chemical and Biomolecular Engineering (BK21 four), Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic of Korea.
Systems Metabolic Engineering and Systems Healthcare Cross-Generation Collaborative Laboratory, Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic of Korea.
出版信息
Proc Natl Acad Sci U S A. 2023 Mar 21;120(12):e2221857120. doi: 10.1073/pnas.2221857120. Epub 2023 Mar 13.
Pfizer's Paxlovid has recently been approved for the emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19. Drug interactions can be a serious medical problem for COVID-19 patients with underlying medical conditions, such as hypertension and diabetes, who have likely been taking other drugs. Here, we use deep learning to predict potential drug-drug interactions between Paxlovid components (nirmatrelvir and ritonavir) and 2,248 prescription drugs for treating various diseases.
辉瑞公司的帕克洛维德（Paxlovid）最近获得了美国食品和药物管理局（FDA）的紧急使用授权（EUA），用于治疗轻度至中度的 COVID-19。对于患有高血压和糖尿病等潜在疾病的 COVID-19 患者，药物相互作用可能是一个严重的医疗问题，因为他们可能已经在服用其他药物。在这里，我们使用深度学习来预测帕克洛维德（nirmatrelvir 和 ritonavir）成分与 2248 种治疗各种疾病的处方药之间潜在的药物相互作用。
Zotero 插件